Press Release

CREATIVE DIAGNOSTICS ANNOUNCES CALPROTECTIN REAGENTS FOR INFLAMMATORY DISEASE RESEARCH



Creative Diagnostics announces the launch of its new line of Calprotectin Reagents to accelerate research in inflammatory diseases.

FOR IMMEDIATE RELEASE

19/05/2023

Creative Diagnostics, a leading global supplier of raw materials, antibodies, and reagents to the biotechnology industry, is proud to announce the launch of its new line of Calprotectin Reagents for the study of inflammation disease.

Calprotectin is an abundant inflammatory marker in the neutrophil cytoplasm, accounting for approximately 45% of total cytoplasmic proteins. It is a member of the S100 calcium-binding family and in mammals (e.g. humans and mice) consists of two proteins, S100A8 and S100A9. In humans, S100A8 is composed of 93 amino acids, while S100A9 is made up of 113 amino acids. Calprotectin has antimicrobial properties that are thought to result from its ability to chelate and sequester pathogenic metal ions. Moreover, both subunits, S100A8 and S100A9, exhibit a wide range of intracellular and extracellular immunomodulatory properties. As a damage-associated molecular pattern (DAMP), calprotectin activates Toll-like receptor 4 (TLR4) and thus contributes to the activation of the innate immune response.

The activation of the intestinal immune system leads to the recruitment of innate immune cells, including neutrophils, which release calprotectin upon activation. As the inflammatory process progresses, the released calprotectin is absorbed into the feces before being excreted from the body. Therefore, the amount of fecal calprotectin is proportional to the number of neutrophils in the gastrointestinal mucosa. In addition, fecal calprotectin has been shown to be highly sensitive and specific for differentiating inflammatory bowel disease (IBD) from irritable bowel syndrome(IBS). High levels of calprotectin indicate IBD, while low or normal levels indicate IBS.

In the United States, an estimated 3.1 million adults have been diagnosed with IBD. Currently, fecal calprotectin testing can be utilized to differentiate IBD from IBS and to monitor the severity of IBD. Creative Diagnostics now offers scientists various calprotectin related antibodies and antigens for quantitative sandwich immunoassays as accurate biomarkers for IBD patients, such as Human Calprotectin ELISA, Magic™ Anti-MRP8/MRP14 monoclonal antibody, Native Calprotectin Antigen, and Recombinant S100a9 protein (human, aa 1-114, >90%) [His].

For example, the Human Calprotectin ELISA Kit is intended for the in vitro quantitative determination of human calprotectin in feces, plasma, serum, sputum and urine samples. This kit is for research use only and is not intended for use in diagnostic or therapeutic procedures. Also, the kit cannot be used to quantify individual MRP-8 (S100A8) or MRP-14 (S100A9) proteins.

Another example is the Recombinant S100a9 protein (human, aa 1-114, >90%) [His], which may be involved in the inhibition of casein kinase. The Recombinant S100A9 protein fused to the C-terminal His-tag is expressed in E. coli and purified by conventional chromatography techniques.

If you want to learn more about Calprotectin Reagents or have any questions regarding research materials, please visit Creative Diagnostics at https://www.creative-diagnostics.com/.

About Creative Diagnostics

Creative Diagnostics is a leading manufacturer and supplier of antibodies, viral antigens, innovative diagnostic components, and critical assay reagents. In addition to providing contract R&D and biologic manufacturing services for diagnostic manufacturers along with GMP biologics manufacturing for the biopharmaceutical market, the company aims to continue to act as a trusted source for all researchers’ assay development and manufacturing needs.

Tags:
Creative Diagnostics  |  Calprotectin Reagents  |  

---

Organisation Profile:
Creative Diagnostics is a leading manufacturer and supplier of antibodies, viral antigens, innovative diagnostic components, and critical assay reagents. We provide contract biologic R&D and manufacturing services to the diagnostic manufacturers along with GMP biologics manufacturing for the biopharmaceutical market. Our goal is to be a trusted source for all your assay development and manufacturing needs.






Press release contact details for Creative Diagnostics

NameCreative Diagnostics
Tel
Fax
Email
Websitehttps://www.creative-diagnostics.com/
OrganisationCreative Diagnostics
Address
Town
County0
Postcode11967




Other press releases from Creative Diagnostics

Creative Diagnostics Launches HPV L1 Antibodies for Neutralization and Vaccine Development
Creative Diagnostics Introduces TCID50 Assay Service for Determining Viral Titers
Creative Diagnostics Introduces ELISA Kit Development Services to Support IVD Research
Creative Diagnostics Introduces Microneutralization Assay Service for Virus Detection
Creative Diagnostics Introduces Virus Yield Reduction Assay Service
Creative Diagnostics Introduces New Low Endotoxin Antibodies for Researchers
Creative Diagnostics Announces Calprotectin Reagents for Inflammatory Disease Research
Creative Diagnostics Introduces Viral Replicon Assay Service to Support Virology Research
Creative Diagnostics Announces the Launch of Radial Immunodiffusion Testing Service
Creative Diagnostics Launches Highly Specific Antibodies Against FXIIIa/F13A1 for Vascular Diseases
Creative Diagnostics Introduces qPCR Assay for Rapid Virus Detection and Quantification
Creative Diagnostics Launches New Reagent Solutions for Herpesvirus Research
Creative Diagnostics Announces New Reagents for Bioanalysis of Antibody Drug Conjugates
Creative Diagnostics Announces New Antimicrobial Susceptibility Testing Services
Creative Diagnostics Introduces New ELISA Kits to Accelerate Autoimmunity Research
Creative Diagnostics Launches Antimicrobial Synergy Testing Services
Creative Diagnostics Launches New Azaperone Test Reagents for Research Applications
Creative Diagnostics Launches Checkerboard Assay Services
Creative Diagnostics Launches New Anti-Small Molecule Label Antibodies to Facilitate NALFIA Development
Creative Diagnostics Announces New CLDN6 Solutions for Cancer Research
Creative Diagnostics Launches Minimum Inhibitory Concentration Testing Services
Creative Diagnostics Launches Carbamazepine Test Reagents
Creative Diagnostics Launches Macrophage Migration Inhibitory Factor Reagents for Research Applications
Creative Diagnostics Announces New Test Reagents for Dapsone
Creative Diagnostics Announces New MBC Assay for Antibacterial Testing Read more: https://www.digitaljournal.com/pr/news/getnews/creative-diagnostics-announces-new-mbc-assay-for-antibacterial-testing#ixzz8KcL65cji
Creative Diagnostics Announces New MBC Assay for Antibacterial Testing
Creative Diagnostics Launches Rapid Robenidine Test Reagents for the Analysis of Anticoccidial Residues
Creative Diagnostics Announces MDT Services for Measuring Antibacterial Effectiveness
Creative Diagnostics Launches New P53 and TP53 Antibodies for Cancer Research
Creative Diagnostics Launches Aflatoxin Test Reagents to Ensure Food Safety
Creative Diagnostics Launches Serum Plate Agglutination Test for In Vitro Detection of Multiple Pathogens
Creative Diagnostics Announces New AAV Reagent Solutions for Gene Therapy
Citrinin Test Reagents for Food Safety
Creative Diagnostics Announces Novel Agar Gel Precipitin Tests for Viral Antigen Detection
Creative Diagnostics Introduces Cutting-Edge Anti-AAV Antibody ELISA Kits for Gene Therapy Research
Creative Diagnostics Announces the Launch of Its Highly Sensitive Kanamycin ELISA Kit for Precise Antibiotic Detection
Creative Diagnostics Launches Comprehensive ELISA Based Assays for Vaccine Development
Creative Diagnostics Announces Comprehensive Vomitoxin Test Reagents for Food Safety Applications

Disclaimer:
Issuers of the press releases are solely responsible for the content of their press releases. Connect2business.co.uk cannot be held liable for the content posted by others to this website.